ArticleFrontiers in medicine2018
Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose.
Article in Frontiers in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Hepatitis E Virus (HEV) Infection in the Context of the One Health Approach: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- The Value of Hepatitis E Screening Sensitivity: Lookback Investigation in German Blood Donors.Viruses · 2026Article
- Hepatitis E in Thailand: From Seroprevalence to Foodborne and Transfusion-Associated Risks.Journal of clinical medicine · 2026Review
- Low Transmission Rate of Hepatitis E Virus by Transfusion of Hepatitis E Virus RNA-Positive Blood Products.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
- Effect of Hepatitis E Virus on the Male Reproductive System: A Review of Current Evidence.Viruses · 2025Review
- The question of screening organ donors for hepatitis e virus: a case report of transmission by kidney transplantation in France and a review of the literature.Virology journal · 2024Review
- Hepatitis E virus infections in German blood donors: results of 8 years of screening, 2015 to 2022.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Article
- Article
- Assessment of Hepatitis E virus transmission risks: a comprehensive review of cases among blood transfusion recipients and blood donors.Infection ecology & epidemiology · 2024Review
- Review
- Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives.Blood transfusion = Trasfusione del sangue · 2023Article
- Is Hepatitis E Virus a Neglected or Emerging Pathogen in Egypt?Pathogens (Basel, Switzerland) · 2022Review
- Fulminant Transfusion-Associated Hepatitis E Virus Infection Despite Screening, England, 2016-2020.Emerging infectious diseases · 2022Article
- Viral hepatitis in 2021: The challenges remaining and how we should tackle them.World journal of gastroenterology · 2022Review
- Transfusion-transmitted hepatitis E: What we know so far?World journal of gastroenterology · 2022Review
- Effect of Hepatitis E Virus RNA Universal Blood Donor Screening, Catalonia, Spain, 2017‒2020.Emerging infectious diseases · 2022Article
- Hepatitis E in Sub Saharan Africa - A significant emerging disease.One health (Amsterdam, Netherlands) · 2021Review
- Hepatitis E Virus Persistence and/or Replication in the Peripheral Blood Mononuclear Cells of Acute HEV-Infected Patients.Frontiers in microbiology · 2021Article
- Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma.Emerging infectious diseases · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The risk and importance of transfusion-transmitted hepatitis E virus (TT-HEV) infections by contaminated blood products is currently a controversial discussed topic in transfusion medicine. The infectious dose, in particular, remains an unknown quantity. In the present study, we illuminate and review this aspect seen from the viewpoint of a blood donation service with more than 2 years of experience in routine HEV blood donor screening. We systematically review the actual status of presently known cases of TT-HEV infections and available routine NAT-screening assays. The review of the literature revealed a significant variation regarding the infectious dose causing hepatitis E. We also present the outcome of six cases confronted with HEV-contaminated blood products, identified by routine HEV RNA screening of minipools using the highly sensitive RealStar HEV RT-PCR Kit (95% LOD: 4.7 IU/mL). Finally, the distribution of viral RNA in different blood components [plasma, red blood cell concentrate (RBC), platelet concentrates (PC)] was quantified using the first WHO international standard for HEV RNA for NAT-based assays. None of the six patients receiving an HEV-contaminated blood product from five different donors (donor 1: RBC, donor 2-5: APC) developed an acute hepatitis E infection, most likely due to low viral load in donor plasma (<100 IU/mL). Of note, the distribution of viral RNA in blood components depends on the plasma content of the component; nonetheless, HEV RNA could be detected in RBCs even when low viral plasma loads of 100-1,000 IU/mL are present. Comprehensive retrospective studies of TT-HEV infection offered further insights into the infectivity of HEV RNA-positive blood products. Minipool HEV NAT screening (96 samples) of blood donations should be adequate as a routine screening assay to identify high viremic donors and will cover at least a large part of viremic phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.